Activation of tumor-associated T cells by immune checkpoint blockade has been one of the most successful immunotherapy approaches for various solid tumors33,34; however, checkpoint inhibitors have been largely ineffective in treating immunologically cold tumors including GBM4,35. As such, the PD-1 in...
tumor-specific peptide vaccination and CAR-T cell immunotherapy have also been explored in the treatment of rGB. Although progress has been made to date, given the antigenic heterogeneity and antigen escape of rGB, the path to achieving immunotherapeutic...
With these encouraging findings, immunotherapy including immune checkpoint blockade, chimeric antigen receptor T (CAR-T) cell therapy, oncolytic virotherapy and vaccine therapy have been actively tested in clinical trials for GBM [23]. Studies are ongoing to use combinatorial therapy with the aim of...
there has been an surge in clinical trials investigating the value of BEV in combination with immunomodulatory agents, such as PD-1 antagonists. Several studies have demonstrated that anti-angiogenic agents can reprogramme the immunosuppressive tumour microenvironment to an...
immunotherapyforglioblastoma CheckMate143 CheckMate143 TransitionfromphaseIItoIII Trialname/TargetpopulationTreatmentarmsPhasePrimaryendpointStatus ClinicalTrials.(asperMarch2016) Identifier CheckMate143FirstrecurrenceofglioblastomaExperimental:nivolumabIIIOSAccrualcompleted ...
Glioblastoma remains essentially incurable, and new therapeutic approaches are urgently needed. Now, the findings of three serial tissue-based studies suggest that immune-checkpoint inhibition can modify the glioblastoma microenvironment. Following these encouraging observations, the results of two phase III ...
Emerging therapies for glioblastomaare focusedon advancing treatment options through immunotherapy, clinical trials, and personalized medicine, offering new hope in the fight against this challenging tumour. Immunotherapy, which manages the body's immune system to fight cancer, is a ...
The recent success of immunotherapy in the treatment of other cancers has renewed interest in vaccine therapy for the treatment of gliomas. In this article, we outline various immunotherapeutic strategies, review recent clinical trials data, and discuss the future of vaccine therapy for glioblastoma. ...
"This is a small study, but it's one in a sequence ofclinical trialswe have conducted to explore the use of an immunotherapy that specifically targets a protein on glioblastoma tumors," said Duke's Kristen Batich, M.D., Ph.D., lead author of a study published online April 14 in the...
6. Immunotherapy Immunotherapy is one of the most promising emerging therapy for GBM, with several clinical trials currently under way. Among the most notable include dendritic cell (DC) cancer vaccines, monoclonal antibodies targeting immune checkpoints, and adoptive T-cell immunotherapy [60]. Althou...